Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the risk of liver cirrhosis and ...

Can-Fite BioPharma (CANF) announced a significant clinical development: the disappearance of episodes of decompensated liver cirrhosis ...

Liver cirrhosis treatment market is estimated to reach approximately $15 billion in the U.S. by 2030Ramat Gan, Israel, Feb. 18, 2025 (GLOBE ...

A study from Massachusetts General Hospital has found that growth hormone may help improve liver health in people with ...

ACLF clinical trials expected to initiate in 1Q253 clinical data readouts expected by year-end 2025 across the ACLF pipeline, including on-going UNVEIL-IT® Phase 2 trialData of on-going Phase 1b ...

Watch what you eat. Fatty buildup in your liver can cause nonalcoholic steatohepatitis and lead to cirrhosis. NASH is linked to high cholesterol, coronary artery disease, obesity, and diabetes.

This inflammation can lead to changes in the liver if it persists. Changes like fibrosis, or scarring of the tissue in the liver, may lead to cirrhosis ... or NASH, is an advanced stage ...

Correspondence to Dr Elisabetta Bugianesi, Department of Medical Sciences, University of Turin, Corso Dogliotti 14, Torino 10126, Italy; elisabetta.bugianesi{at}unito.it; Dr Quentin Mark Anstee, ...

prevention of liver injury following hypovolaemic shock and preventing/delaying progression of cirrhosis of any aetiology. Moreover, statins have been shown to have potential beneficial effects in the ...

Our success reflects exceptional execution and the urgent need for treatments for this serious liver disease ... the MAESTRO-NASH OUTCOMES trial in compensated cirrhosis could unlock further ...

NASH kNOWledge, a non-profit corporation established to provide education and increase public awareness of non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH), recently ...